Global Self Amplifying RNA Vaccines Market Report, Forecast: By Route of Administration: Intradermal, Intranasal, Intramuscular, Others; By Application: Influenza, Rabies, HIV-1, COVID-19, Respiratory Syncytial Virus (RSV), Ebola, Others; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Self Amplifying RNA Vaccines Market Overview 
    3.1    Global Self Amplifying RNA Vaccines Market Historical Value (2017-2023) 
    3.2    Global Self Amplifying RNA Vaccines Market Forecast Value (2024-2032)
4    Vendor  Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Global Self Amplifying RNA Vaccines Market Landscape*
    5.1    Global Self Amplifying RNA Vaccines Market: Developers Landscape
        5.1.1    Analysis by Year of Establishment
        5.1.2    Analysis by Company Size
        5.1.3    Analysis by Region
    5.2    Global Self Amplifying RNA Vaccines Market: Product Landscape 
        5.2.1    Analysis by Route of Administration
        5.2.2    Analysis by Application
6    Global Self Amplifying RNA Vaccines Market Dynamics
    6.1    Market Drivers and Constraints
    6.2    SWOT Analysis
        6.2.1    Strengths
        6.2.2    Weaknesses
        6.2.3    Opportunities
        6.2.4    Threats
    6.3    PESTEL Analysis
        6.3.1    Political
        6.3.2    Economic
        6.3.3    Social
        6.3.4    Technological
        6.3.5    Legal
        6.3.6    Environment
    6.4    Porter’s Five Forces Model
        6.4.1    Bargaining Power of Suppliers
        6.4.2    Bargaining Power of Buyers
        6.4.3    Threat of New Entrants
        6.4.4    Threat of Substitutes
        6.4.5    Degree of Rivalry
    6.5    Key Demand Indicators 
    6.6    Key Price Indicators
    6.7    Industry Events, Initiatives, and Trends  
    6.8    Value Chain Analysis
7    Global Self  Amplifying RNA Vaccines Market Segmentation (2017-2032)
    7.1    Global Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
        7.1.1    Market Overview
        7.1.2    Intradermal
        7.1.3    Intranasal
        7.1.4    Intramuscular
        7.1.5    Others
    7.2    Global Self Amplifying RNA Vaccines Market (2017-2032) by Application
        7.2.1    Market Overview
        7.2.2    Influenza
        7.2.3    Rabies
        7.2.4    HIV-1
        7.2.5    COVID-19
        7.2.6    Respiratory Syncytial Virus (RSV)
        7.2.7    Ebola
        7.2.8    Others
    7.3    Global Self Amplifying RNA Vaccines Market (2017-2032) by Region
        7.3.1    Market Overview
        7.3.2    North America
        7.3.3    Europe 
        7.3.4    Asia Pacific
        7.3.5    Latin America
        7.3.6    Middle East and Africa
8    North America Self Amplifying RNA Vaccines Market (2017-2032)
    8.1    North America Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
        8.1.1    Market Overview
        8.1.2    Intradermal
        8.1.3    Intranasal
        8.1.4    Intramuscular
        8.1.5    Others
    8.2    North America Self Amplifying RNA Vaccines Market (2017-2032) by Application
        8.2.1    Market Overview
        8.2.2    Influenza
        8.2.3    Rabies
        8.2.4    HIV-1
        8.2.5    COVID-19
        8.2.6    Respiratory Syncytial Virus (RSV)
        8.2.7    Ebola
        8.2.8    Others
    8.3    North America Self Amplifying RNA Vaccines Market (2017-2032) by Country
        8.3.1    United States of America
        8.3.2    Canada
9    Europe Self Amplifying RNA Vaccines Market (2017-2032)
    9.1    Europe Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
        9.1.1    Market Overview
        9.1.2    Intradermal
        9.1.3    Intranasal
        9.1.4    Intramuscular
        9.1.5    Others
    9.2    Europe Self Amplifying RNA Vaccines Market (2017-2032) by Application
        9.2.1    Market Overview
        9.2.2    Influenza
        9.2.3    Rabies
        9.2.4    HIV-1
        9.2.5    COVID-19
        9.2.6    Respiratory Syncytial Virus (RSV)
        9.2.7    Ebola
        9.2.8    Others
    9.3    Europe Self Amplifying RNA Vaccines Market (2017-2032) by Country
        9.3.1    United Kingdom
        9.3.2    Germany
        9.3.3    France
        9.3.4    Italy
        9.3.5    Others
10    Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032)
    10.1    Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
        10.1.1    Market Overview
        10.1.2    Intradermal
        10.1.3    Intranasal
        10.1.4    Intramuscular
        10.1.5    Others
    10.2    Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Application
        10.2.1    Market Overview
        10.2.2    Influenza
        10.2.3    Rabies
        10.2.4    HIV-1
        10.2.5    COVID-19
        10.2.6    Respiratory Syncytial Virus (RSV)
        10.2.7    Ebola
        10.2.8    Others
    10.3    Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Country
        10.3.1    China
        10.3.2    Japan
        10.3.3    India
        10.3.4    ASEAN
        10.3.5    Australia
        10.3.6    Others
11    Latin America Self Amplifying RNA Vaccines Market (2017-2032)
    11.1    Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
        11.1.1    Market Overview
        11.1.2    Intradermal
        11.1.3    Intranasal
        11.1.4    Intramuscular
        11.1.5    Others
    11.2    Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Application
        11.2.1    Market Overview
        11.2.2    Influenza
        11.2.3    Rabies
        11.2.4    HIV-1
        11.2.5    COVID-19
        11.2.6    Respiratory Syncytial Virus (RSV)
        11.2.7    Ebola
        11.2.8    Others
    11.3    Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Country
        11.3.1    Brazil
        11.3.2    Argentina
        11.3.3    Mexico
        11.3.4    Others
12    Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032)
    12.1    Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
        12.1.1    Market Overview
        12.1.2    Intradermal
        12.1.3    Intranasal
        12.1.4    Intramuscular
        12.1.5    Others
    12.2    Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Application
        12.2.1    Market Overview
        12.2.2    Influenza
        12.2.3    Rabies
        12.2.4    HIV-1
        12.2.5    COVID-19
        12.2.6    Respiratory Syncytial Virus (RSV)
        12.2.7    Ebola
        12.2.8    Others
    12.3    Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Country
        12.3.1    Saudi Arabia
        12.3.2    United Arab Emirates
        12.3.3    Nigeria
        12.3.4    South Africa
        12.3.5    Others
13    Regulatory Framework
    13.1    Regulatory Overview
    13.2    US FDA
    13.3    EU EMA
    13.4    INDIA CDSCO
    13.5    JAPAN PMDA
    13.6    Others
14    Patent Analysis
    14.1     Analysis by Type of Patent
    14.2     Analysis by Publication Year
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Patent Age
    14.5     Analysis by CPC Analysis
    14.6     Analysis by Patent Valuation 
    14.7     Analysis by Key Players
15    Clinical Trial Analysis
    15.1    Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area
    15.5    Analysis by Geography
16    Grants  Analysis
    16.1    Analysis by Year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Application
    16.5    Analysis by Funding Institute
    16.6    Analysis by NIH Departments
    16.7    Analysis by Recipient Organization 
17    Funding and Investment Analysis
    17.1    Analysis by Funding Instances
    17.2    Analysis by Type of Funding
    17.3    Analysis by Funding Amount
    17.4    Analysis by Leading Players
    17.5    Analysis by Leading Investors
    17.6    Analysis by Geography
18    Strategic Initiatives
    18.1    Analysis by Partnership Instances
    18.2    Analysis by Type of Partnership and Collaborations
    18.3    Analysis by Joint Ventures
    18.4    Analysis by Leading Players
    18.5    Analysis by Geography 
19    Supplier Landscape
    19.1    Market Share Analysis, By Region (Top 5 Companies)
        19.1.1    Market Share Analysis: Global
        19.1.2    Market Share Analysis: North America
        19.1.3    Market Share Analysis: Europe
        19.1.4    Market Share Analysis: Asia Pacific
        19.1.5    Market Share Analysis: Others
    19.2    Gennova Biopharmaceuticals Limited  
        19.2.1    Financial Analysis
        19.2.2    Product Portfolio
        19.2.3    Demographic Reach and Achievements
        19.2.4    Company News and Development
        19.2.5    Certifications 
    19.3    Arcturus Therapeutics, Inc.
        19.3.1    Financial Analysis
        19.3.2    Product Portfolio
        19.3.3    Demographic Reach and Achievements
        19.3.4    Company News and Development
        19.3.5    Certifications
    19.4    VLP Therapeutics Japan, LLC
        19.4.1    Financial Analysis
        19.4.2    Product Portfolio
        19.4.3    Demographic Reach and Achievements
        19.4.4    Company News and Development
        19.4.5    Certifications
    19.5    CSL Limited
        19.5.1    Financial Analysis
        19.5.2    Product Portfolio
        19.5.3    Demographic Reach and Achievements
        19.5.4    Company News and Development
        19.5.5    Certifications
    19.6    TriLink BioTechnologies
        19.6.1    Financial Analysis
        19.6.2    Product Portfolio
        19.6.3    Demographic Reach and Achievements
        19.6.4    Company News and Development
        19.6.5    Certifications
    19.7    ImmunityBio, Inc.
        19.7.1    Financial Analysis
        19.7.2    Product Portfolio
        19.7.3    Demographic Reach and Achievements
        19.7.4    Company News and Development
        19.7.5    Certifications
    19.8    Pfizer Inc. 
        19.8.1    Financial Analysis
        19.8.2    Product Portfolio
        19.8.3    Demographic Reach and Achievements
        19.8.4    Company News and Development
        19.8.5    Certifications
    19.9    Gritstone bio, Inc.
        19.9.1    Financial Analysis
        19.9.2    Product Portfolio
        19.9.3    Demographic Reach and Achievements
        19.9.4    Company News and Development
        19.9.5    Certifications
    19.10    eTheRNA Immunotherapies NV
        19.10.1    Financial Analysis
        19.10.2    Product Portfolio
        19.10.3    Demographic Reach and Achievements
        19.10.4    Company News and Development
        19.10.5    Certifications
20    Global Self Amplifying RNA Vaccines Market – Distribution Model (Additional Insight)
    20.1     Overview 
    20.2     Potential Distributors 
    20.3     Key Parameters for Distribution Partner Assessment 
21    Key Opinion Leaders (KOL) Insights (Additional Insight)

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.